Updated guidelines for pharmacologic treatment of perinatal depression: Understanding medication options
Rebeca Ortiz Worthington1, Zehra Aftab2, Nicole Leong3
1Department of Medicine, Division of General Internal Medicine, University of Chicago, Chicago, IL Rebeca.OrtizWorthington@bsd.uchicago.edu.
None:
The 2023 American College of Obstetricians and Gynecologists (ACOG) guideline on perinatal mental health conditions recommends prescribing and titrating pharmacotherapy for perinatal depression, with the selective serotonin reuptake inhibitors sertraline and escitalopram as first-line medications for patients who have not previously taken any medications for mood disorders. A subsequent ACOG Clinical Practice Update addresses zuranolone for postpartum depression. The authors present an overview of the guideline's recommendations on pharmacotherapy for treating perinatal depression and summarize actionable recommendations for nonpsychiatric clinicians.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Drug Therapy
Antianxiety Medications
Mania and Antimanic Drugs: Overview
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...


